1. Home
  2. KZIA vs JNVR Comparison

KZIA vs JNVR Comparison

Compare KZIA & JNVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KZIA
  • JNVR
  • Stock Information
  • Founded
  • KZIA 1994
  • JNVR 2018
  • Country
  • KZIA Australia
  • JNVR United States
  • Employees
  • KZIA N/A
  • JNVR N/A
  • Industry
  • KZIA Biotechnology: Pharmaceutical Preparations
  • JNVR Finance: Consumer Services
  • Sector
  • KZIA Health Care
  • JNVR Finance
  • Exchange
  • KZIA Nasdaq
  • JNVR Nasdaq
  • Market Cap
  • KZIA 6.0M
  • JNVR 7.0M
  • IPO Year
  • KZIA 1999
  • JNVR 2023
  • Fundamental
  • Price
  • KZIA $0.89
  • JNVR $5.04
  • Analyst Decision
  • KZIA Strong Buy
  • JNVR
  • Analyst Count
  • KZIA 2
  • JNVR 0
  • Target Price
  • KZIA $11.50
  • JNVR N/A
  • AVG Volume (30 Days)
  • KZIA 5.5M
  • JNVR 14.3K
  • Earning Date
  • KZIA 03-26-2025
  • JNVR 03-27-2025
  • Dividend Yield
  • KZIA N/A
  • JNVR N/A
  • EPS Growth
  • KZIA N/A
  • JNVR N/A
  • EPS
  • KZIA N/A
  • JNVR N/A
  • Revenue
  • KZIA $1,655,324.00
  • JNVR $1,820,969.00
  • Revenue This Year
  • KZIA $806.89
  • JNVR N/A
  • Revenue Next Year
  • KZIA N/A
  • JNVR N/A
  • P/E Ratio
  • KZIA N/A
  • JNVR N/A
  • Revenue Growth
  • KZIA 248000.00
  • JNVR N/A
  • 52 Week Low
  • KZIA $0.89
  • JNVR $3.37
  • 52 Week High
  • KZIA $15.80
  • JNVR $11.84
  • Technical
  • Relative Strength Index (RSI)
  • KZIA 28.96
  • JNVR 45.24
  • Support Level
  • KZIA $0.90
  • JNVR $4.91
  • Resistance Level
  • KZIA $1.60
  • JNVR $5.35
  • Average True Range (ATR)
  • KZIA 0.24
  • JNVR 0.38
  • MACD
  • KZIA 0.01
  • JNVR -0.04
  • Stochastic Oscillator
  • KZIA 0.00
  • JNVR 9.20

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

About JNVR Janover Inc.

Janover Inc is a B2B fintech marketplace providing a platform for commercial property borrowers and lenders. It provides a technology platform that connects commercial mortgage borrowers looking for debt to refinance, build, or buy commercial property including apartment buildings to commercial property lenders including banks, credit unions, REITs, debt funds, and more looking to deploy capital into commercial mortgages. The firm caters to two consumer segments: lenders and borrowers. It derives the majority of its revenue from transaction fees.

Share on Social Networks: